0VF9 Stock Chart & Stats
C$0.12
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.12
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)2.26K
Market Cap
C$32.71M
Enterprise ValueC$139.82
Total Cash (Recent Filing)C$79.87K
Total Debt (Recent Filing)C$77.62M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding344,286,700
10 Day Avg. Volume0
30 Day Avg. Volume2,264
Financial Highlights & Ratios
PEG Ratio-7.26
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Therapeutic FocusA focused scientific platform targeting BET proteins and epigenetic mechanisms gives Resverlogix a defined area of expertise and research identity. Concentration on cardiometabolic and chronic diseases may support coherent clinical development and preserve longer-term partnering potential.
Multiple Potential Funding ChannelsThe clinical-stage model provides several potential routes to fund development beyond product sales, including licensing payments, milestones, royalties, reimbursements, and financing. This flexibility could support continued programs if the company secures suitable partners or capital.
Cash Burn Below Earlier PeakAlthough cash generation remains negative, the current burn rate is not worse than every prior period, with 2021 described as more severe. Relative stability in consumption could provide some operational planning benefit, even though external funding remains necessary.
Bears Say
No Revenue BaseThe absence of revenue leaves Resverlogix without recurring operating income to support research, administration, or future clinical programs. Continued negative gross profit and operating metrics indicate that the business has not yet established commercial scale or self-sustaining demand.
Persistent Worsening LossesLarge recurring losses, including a wider TTM loss than the prior annual period, increase dependence on outside financing and reduce visibility into a path toward profitability. Ongoing losses can constrain development choices and make future capital requirements more persistent.
Severely Stressed Balance SheetNegative equity and debt that substantially exceeds the asset base indicate limited financial flexibility and elevated solvency pressure. This capital structure may restrict investment in development, increase refinancing dependence, and heighten the risk of dilution or restructuring.
Resverlogix News
0VF9 FAQ
What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest share price was C$0.09 and its highest was C$0.12 in the past 12 months.
What is Resverlogix Corp. J’s market cap?
Resverlogix Corp. J’s market cap is C$32.71M.
When is Resverlogix Corp. J’s upcoming earnings report date?
Resverlogix Corp. J’s upcoming earnings report date is Nov 06, 2026 which is in 36 days.
How were Resverlogix Corp. J’s earnings last quarter?
Resverlogix Corp. J released its earnings results on Aug 14, 2026. The company reported -C$0.026 earnings per share for the quarter.
Is Resverlogix Corp. J overvalued?
According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued.
Does Resverlogix Corp. J pay dividends?
Resverlogix Corp. J does not currently pay dividends.
What is Resverlogix Corp. J’s EPS estimate?
Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. J have?
Resverlogix Corp. J has 344,286,700 shares outstanding.
What happened to Resverlogix Corp. J’s price movement after its last earnings report?
Resverlogix Corp. J reported an EPS of -C$0.026 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Resverlogix Corp. J?
Currently, no hedge funds are holding shares in GB:0VF9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Resverlogix Corp. J
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Technical Analysis
―
BriaCell Therapeutics
―
Microbix Biosystms
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―